Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA

Comparative cancer survival in European countries

(2014) A. J. Munro   BRITISH MEDICAL BULLETIN

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states

(2013) F. Ades et al.   ANNALS OF ONCOLOGY

Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980

(2013) C. Bosetti et al.   ANNALS OF ONCOLOGY

Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab

(2013) C. Leopold et al.   HEALTH POLICY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

The unequal health of Europeans: successes and failures of policies

(2013) Johan P Mackenbach et al.   LANCET

Economic burden of cancer across the European Union: a population-based cost analysis

(2013) Ramon Luengo-Fernandez et al.   LANCET ONCOLOGY

Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study

(2013) Roberta De Angelis et al.   LANCET ONCOLOGY

The weight of nations: an estimation of adult human biomass

(2012) Sarah Catherine Walpole et al.   BMC PUBLIC HEALTH

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials

(2011)   LANCET

National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants

(2011) Mariel M Finucane et al.   LANCET

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival

(2010) Fatemeh Asadzadeh Vostakolaei et al.   EUROPEAN JOURNAL OF PUBLIC HEALTH

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

(2009) Marc Spielmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY